We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AB SCIEX and the University of Melbourne Partner to Develop Approach to Drug Metabolism Studies of Biopharmaceuticals

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AB SCIEX and the University of Melbourne Partner to Develop Approach to Drug Metabolism Studies of Biopharmaceuticals"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
AB SCIEX and the University of Melbourne have announced a joint technology development project to improve drug metabolism studies of biopharmaceuticals. This project is focused on developing a standardized testing methodology based on a breakthrough approach that scientists at the University of Melbourne pioneered on the AB SCIEX QTRAP® 5500 System as the life science industry’s first way to follow the fate of the breakdown of protein-based drugs in vivo.

This approach could help drug discovery scientists better determine the effectiveness and safety of peptide and protein therapeutic agents that are advanced through regulatory processes and ultimately sold on the consumer market.

Biopharmaceutical development is the area within the pharmaceutical industry. Approximately one-third of all pipeline products in active development are biopharmaceuticals. Regulatory requirements for assessments of these protein-based drugs, or biologics, are expected to rapidly evolve, requiring a description of a drug’s metabolism and how it may affect overall elimination of the drug from the body. The way it metabolizes can significantly affect the drug’s efficacy and safety.

Drug discovery scientists currently do not have the ability to follow the fate of the breakdown of protein-based drugs in vivo without knowing what they are ahead of time. Providing this capability is critical for advancing drug metabolism studies of biopharmaceuticals. To address this need, scientists at the University of Melbourne invented a new approach using mass spectrometry to do these tests and are partnering with AB SCIEX with the goal of making the new solution available to any scientist conducting these types of studies.

Large biopharmaceutical companies as well as pharmaceutical companies with growing biopharma operations have already provided positive feedback about this mass spectrometry-based approach. To ensure that the new solution meets the evolving requirements for drug discovery and development, AB SCIEX will continue to engage with biopharmaceutical scientists around the world to obtain feedback, share scientific insight and refine the novel approach.

This development project is based on AB SCIEX mass spectrometry technology. The team of developers is customizing the approach for QTRAP technology as well as the AB SCIEX TripleTOF™ 5600 System, the high-resolution mass spectrometer for high-performance qualitative and quantitative analysis. As part of the project, the developers are developing a new workflow and creating specialized software to centrally manage it, giving drug discovery scientists more control.

Anthony Purcell, Ph.D., Associate Professor, Senior Research Fellow and a Principal Investigator at the Department of Biochemistry and Molecular Biology, The Bio21 Molecular Science and Biotechnology Institute at the University of Melbourne: “Targeting the unknown breakdown products of a biologic without knowing what they are is revolutionary in the biopharmaceutical industry. The technology we are developing with AB SCIEX will give scientists the unique ability to produce metabolism profiles for peptide and protein drugs that the industry simply cannot do right now. This is essential for advancing an increasing number of biopharma drugs to market.”